-1195 A/G promoter variants of the cyclooxygenase-2 gene increases the risk of pain occurrence in endometriotic women

H Wang, Liangzhong Sun, L Sun, Majun Jiang, M Jiang, L Liu, G Wang
Clinical and experimental obstetrics & gynecology · 2016 · vol. 43(2) , pp. 254–257 · doi:10.12891/ceog2768.2016 · PMID:27132422 · W2376905443
article OA: bronze CC0 ⤵ 4 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

The -1195 A/G polymorphism in the COX-2 gene promoter is associated with an increased risk of pain in women with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text ⓘ

This study evaluated whether the -1195 A/G polymorphism in the cyclooxygenase-2 (COX-2) promoter region is associated with endometriosis and pain in a Chinese population. Using PCR-RFLP, the authors compared 32 women with endometriosis who had pain, 28 women with endometriosis without pain, and 29 healthy controls, and found that AA homozygote carriers and A allele frequencies were significantly higher in endometriosis patients than in controls. In subgroup analysis, the AA genotype and A allele were more frequent in the severe pain group than in mild/moderate groups, and the presence of an -1195 AA-containing haplotype was associated with higher risk of endometriosis (2.86-fold) and pain in endometriosis (2.33-fold). The paper’s main limitation is the small sample size, which restricts generalizability. This paper is centrally about endometriosis — it tests COX-2 promoter -1195 A/G variants as risk factors for pain occurrence and severity in women with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: The aim of this study was to evaluate the association between -1195 A/G polymorphism in cyclooxygenase-2 (COX-2) gene and the risk of pain occurrence in women with endometriosis (EM). MATERIALS AND METHODS: -1195 A/G polymorphism in the promoter region of COX-2 gene was analyzed in 32 EM patients with pain, 28 EM patients without pain, and 29 healthy controls in a Chinese population using a PCR-RFLP assay. RESULTS: AA homozygote carriers and A allelic frequencies for -1195 A/G polymorphism in COX-2 gene were significantly increased in EM patients compared with the healthy controls (p < 0.001). In addition, further subgroup analysis revealed that the AA genotype and A allele of the -1195 A/G variant were present at a significantly higher frequency in the severe pain group than those in the mild and moderate pain groups. Compared with the controls, the risk of developing EM was 2.86-fold higher in individuals with -1195 AA containing the haplotype, and the risk of developing pain was 2.33-fold higher in EM patients with -1195 AA containing the haplotype. CONCLUSIONS: These findings suggest that the -1195 A/G on the promoter region of COX-2 gene may increase the risk of pain occurrence in EM women, possibly by affecting the rate of gene expression, especially in patients with the pain phenotype.
Full text 1,937 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Objective: The aim of this study was to evaluate the association between -1195 A/G polymorphism in cyclooxygenase -2 (COX-2) gene and the risk of pain occurrence in women with endometriosis (EM). Materials and Methods: -1195 A/G polymorphism in the promoter region of COX-2 gene was analyzed in 32 EM patients with pain, 28 EM patients without pain, and 29 healthy controls in a Chinese population using a PCR-RFLP assay. Results: AA homozygote carriers and A allelic frequencies for -1195 A/G polymorphism in COX-2 gene were significantly increased in EM patients compared with the healthy controls (p < 0.001). In addition, further subgroup analysis revealed that the AA genotype and A allele of the -1195 A/G variant were present at a significantly higher frequency in the severe pain group than those in the mild and moderate pain groups. Compared with the controls, the risk of developing EM was 2.86-fold higher in individuals with -1195 AA containing the haplotype, and the risk of developing pain was 2.33-fold higher in EM patients with -1195 AA containing the haplotype. Conclusions: These findings suggest that the -1195 A/G on the promoter region of COX-2 gene may increase the risk of pain occurrence in EM women, possibly by affecting the rate of gene expression, especially in patients with the pain phenotype.

Keywords

- Endometriosis - Pain - Cyclooxygenase-2 - Single nucleotide polymorphism

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Cyclooxygenase 2 Endometriosis Ovarian Diseases Pain Adult Asian People Asian People Biological Assay Case-Control Studies Cyclooxygenase 2 Endometriosis Endometriosis Female Gene Expression Gene Frequency Genotype Haplotypes Humans Ovarian Diseases Ovarian Diseases

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (18)

Cited by (4)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:21:07.355239+00:00
License: CC0 · commercial use OK